154 related articles for article (PubMed ID: 20657384)
1. Ribozyme-mediated inhibition of 801-bp deletion-mutant epidermal growth factor receptor mRNA expression in glioblastoma multiforme.
Karpel-Massler G; Wirtz CR; Halatsch ME
Molecules; 2010 Jun; 15(7):4670-8. PubMed ID: 20657384
[TBL] [Abstract][Full Text] [Related]
2. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA.
Halatsch ME; Schmidt U; Bötefür IC; Holland JF; Ohnuma T
J Neurosurg; 2000 Feb; 92(2):297-305. PubMed ID: 10659018
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
Kalman B; Szep E; Garzuly F; Post DE
Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
[TBL] [Abstract][Full Text] [Related]
4. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
[TBL] [Abstract][Full Text] [Related]
5. The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms.
Loew S; Schmidt U; Unterberg A; Halatsch ME
Anticancer Agents Med Chem; 2009 Jul; 9(6):703-15. PubMed ID: 19601750
[TBL] [Abstract][Full Text] [Related]
6. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
[TBL] [Abstract][Full Text] [Related]
7. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract][Full Text] [Related]
8. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
Chistiakov DA; Chekhonin IV; Chekhonin VP
Eur J Pharmacol; 2017 Sep; 810():70-82. PubMed ID: 28583430
[TBL] [Abstract][Full Text] [Related]
9. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
Taylor TE; Furnari FB; Cavenee WK
Curr Cancer Drug Targets; 2012 Mar; 12(3):197-209. PubMed ID: 22268382
[TBL] [Abstract][Full Text] [Related]
10. Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR
von Achenbach C; Silginer M; Blot V; Weiss WA; Weller M
Mol Cancer Ther; 2020 Jun; 19(6):1328-1339. PubMed ID: 32371586
[TBL] [Abstract][Full Text] [Related]
11. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.
Mukherjee B; McEllin B; Camacho CV; Tomimatsu N; Sirasanagandala S; Nannepaga S; Hatanpaa KJ; Mickey B; Madden C; Maher E; Boothman DA; Furnari F; Cavenee WK; Bachoo RM; Burma S
Cancer Res; 2009 May; 69(10):4252-9. PubMed ID: 19435898
[TBL] [Abstract][Full Text] [Related]
12. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
[TBL] [Abstract][Full Text] [Related]
13. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
[TBL] [Abstract][Full Text] [Related]
14. Crizotinib and erlotinib inhibits growth of c-Met
Goodwin CR; Rath P; Oyinlade O; Lopez H; Mughal S; Xia S; Li Y; Kaur H; Zhou X; Ahmed AK; Ho S; Olivi A; Lal B
Clin Neurol Neurosurg; 2018 Aug; 171():26-33. PubMed ID: 29803091
[TBL] [Abstract][Full Text] [Related]
15. Suppression of EGFRvIII-mediated proliferation and tumorigenesis of breast cancer cells by ribozyme.
Luo X; Gong X; Tang CK
Int J Cancer; 2003 May; 104(6):716-21. PubMed ID: 12640678
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.
An Z; Aksoy O; Zheng T; Fan QW; Weiss WA
Oncogene; 2018 Mar; 37(12):1561-1575. PubMed ID: 29321659
[TBL] [Abstract][Full Text] [Related]
17. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling.
Huang HS; Nagane M; Klingbeil CK; Lin H; Nishikawa R; Ji XD; Huang CM; Gill GN; Wiley HS; Cavenee WK
J Biol Chem; 1997 Jan; 272(5):2927-35. PubMed ID: 9006938
[TBL] [Abstract][Full Text] [Related]
18. EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma.
Yeo AT; Jun HJ; Appleman VA; Zhang P; Varma H; Sarkaria JN; Charest A
Oncogene; 2021 Apr; 40(15):2682-2696. PubMed ID: 33707748
[TBL] [Abstract][Full Text] [Related]
19. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]